Molecular Response: Crown Bioscience, Inc. Buys PDX Unit From Molecular Response (MRL)

February 18, 2015 -- Crown Bioscience, a US-China preclinical CRO with a focus on oncology, added to its offerings by acquiring diagnostic oncology assets from Molecular Response of San Diego. Crown bought MRLs PDX bank of several hundred established models for in vivo pharmacology services along with several other models under development. It also acquired access to 8,000 viable human tumors for...